Literature DB >> 35430873

The IFNγ-PDL1 Pathway Enhances CD8T-DCT Interaction to Promote Hypertension.

Lance N Benson1, Yunmeng Liu1,2, Xiangting Wang1,2, Yunzhao Xiong1, Sung W Rhee1, Yunping Guo1, Katherine S Deck1, Christoph J Mora1, Lin-Xi Li3, Lu Huang3, J Tucker Andrews3, Zhiqiang Qin4, Robert S Hoover5, Benjamin Ko6, Ryan M Williams7, Daniel A Heller8, Edgar A Jaimes9, Shengyu Mu1.   

Abstract

BACKGROUND: Renal T cells contribute importantly to hypertension, but the underlying mechanism is incompletely understood. We reported that CD8Ts directly stimulate distal convoluted tubule cells (DCTs) to increase NCC (sodium chloride co-transporter) expression and salt reabsorption. However, the mechanistic basis of this pathogenic pathway that promotes hypertension remains to be elucidated.
METHODS: We used mouse models of DOCA+salt (DOCA) treatment and adoptive transfer of CD8+ T cells (CD8T) from hypertensive animals to normotensive animals in in vivo studies. Co-culture of mouse DCTs and CD8Ts was used as in vitro model to test the effect of CD8T activation in promoting NCC-mediated sodium retention and to identify critical molecular players contributing to the CD8T-DCT interaction. Interferon (IFNγ)-KO mice and mice receiving renal tubule-specific knockdown of PDL1 were used to verify in vitro findings. Blood pressure was continuously monitored via radio-biotelemetry, and kidney samples were saved at experimental end points for analysis.
RESULTS: We identified critical molecular players and demonstrated their roles in augmenting the CD8T-DCT interaction leading to salt-sensitive hypertension. We found that activated CD8Ts exhibit enhanced interaction with DCTs via IFN-γ-induced upregulation of MHC-I and PDL1 in DCTs, thereby stimulating higher expression of NCC in DCTs to cause excessive salt retention and progressive elevation of blood pressure. Eliminating IFN-γ or renal tubule-specific knockdown of PDL1 prevented T cell homing into the kidney, thereby attenuating hypertension in 2 different mouse models.
CONCLUSIONS: Our results identified the role of activated CD8Ts in contributing to increased sodium retention in DCTS through the IFNγ-PDL1 pathway. These findings provide a new mechanism for T cell involvement in the pathogenesis of hypertension and reveal novel therapeutic targets.

Entities:  

Keywords:  blood pressure; hypertension; immunity; interferon; sodium chloride

Mesh:

Substances:

Year:  2022        PMID: 35430873      PMCID: PMC9106883          DOI: 10.1161/CIRCRESAHA.121.320373

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   23.213


  65 in total

1.  Mesoscale nanoparticles selectively target the renal proximal tubule epithelium.

Authors:  Ryan M Williams; Janki Shah; Brandon D Ng; Denise R Minton; Lorraine J Gudas; Christopher Y Park; Daniel A Heller
Journal:  Nano Lett       Date:  2015-03-26       Impact factor: 11.189

Review 2.  Cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Jiun-Ruey Hu; Roberta Florido; Evan J Lipson; Jarushka Naidoo; Reza Ardehali; Carlo G Tocchetti; Alexander R Lyon; Robert F Padera; Douglas B Johnson; Javid Moslehi
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

3.  Renal transporter activation during angiotensin-II hypertension is blunted in interferon-γ-/- and interleukin-17A-/- mice.

Authors:  Nikhil V Kamat; Salim R Thabet; Liang Xiao; Mohamed A Saleh; Annet Kirabo; Meena S Madhur; Eric Delpire; David G Harrison; Alicia A McDonough
Journal:  Hypertension       Date:  2015-01-19       Impact factor: 10.190

4.  Hypertension and kidney disease progression.

Authors:  Diego Rigo; Marcelo Orias
Journal:  Clin Nephrol       Date:  2020 Supplement Jan       Impact factor: 0.975

Review 5.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

6.  Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension.

Authors:  Jong-Chan Youn; Hee Tae Yu; Beom Jin Lim; Myoung Ju Koh; Jino Lee; Dong-Yeop Chang; Yoon Seok Choi; Sang-Hak Lee; Seok-Min Kang; Yangsoo Jang; Ook Joon Yoo; Eui-Cheol Shin; Sungha Park
Journal:  Hypertension       Date:  2013-05-28       Impact factor: 10.190

7.  Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells.

Authors:  Roland Schoop; Patricia Wahl; Michel Le Hir; Uwe Heemann; Minghui Wang; Rudolf P Wüthrich
Journal:  Nephrol Dial Transplant       Date:  2004-09-07       Impact factor: 5.992

8.  Activation of Human T Cells in Hypertension: Studies of Humanized Mice and Hypertensive Humans.

Authors:  Hana A Itani; William G McMaster; Mohamed A Saleh; Rafal R Nazarewicz; Tomasz P Mikolajczyk; Anna M Kaszuba; Anna Konior; Aleksander Prejbisz; Andrzej Januszewicz; Allison E Norlander; Wei Chen; Rachel H Bonami; Andrew F Marshall; Greg Poffenberger; Cornelia M Weyand; Meena S Madhur; Daniel J Moore; David G Harrison; Tomasz J Guzik
Journal:  Hypertension       Date:  2016-05-23       Impact factor: 10.190

9.  Tissue expression of PD-L1 mediates peripheral T cell tolerance.

Authors:  Mary E Keir; Spencer C Liang; Indira Guleria; Yvette E Latchman; Andi Qipo; Lee A Albacker; Maria Koulmanda; Gordon J Freeman; Mohamed H Sayegh; Arlene H Sharpe
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

10.  Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.

Authors:  Tomasz J Guzik; Nyssa E Hoch; Kathryn A Brown; Louise A McCann; Ayaz Rahman; Sergey Dikalov; Jorg Goronzy; Cornelia Weyand; David G Harrison
Journal:  J Exp Med       Date:  2007-09-17       Impact factor: 14.307

View more
  1 in total

1.  Formulation of Lipid-Free Polymeric Mesoscale Nanoparticles Encapsulating mRNA.

Authors:  Rachel Skelton; Arantxa Roach; Lauren E Prudhomme; Jing Yu Carolina Cen Feng; Pooja Gaikwad; Ryan M Williams
Journal:  Pharm Res       Date:  2022-09-26       Impact factor: 4.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.